8-K: Alumis Updates Investor Deck, Eyes Q1 2026 Data Readout

Alumis Inc. updated its corporate presentation, showcasing a late-stage precision immunology pipeline and key near-term data readouts.

Summary

• Alumis Inc. updated its corporate presentation for investors and analysts on September 3, 2025.
• The company has a portfolio of three clinical molecules: Envudeucitinib (TYK2 inhibitor for Psoriasis and SLE), A-005 (CNS penetrant TYK2 inhibitor for MS), and Lonigutamab (anti-IGF-1R therapy for Thyroid Eye Disease).
• Envudeucitinib Phase 3 top-line data for Psoriasis is expected early Q1 2026, and Phase 2b top-line data for SLE is expected Q3 2026.
• A-005 Phase 2 initiation in Multiple Sclerosis is planned for 1H 2026.
• Cash, cash equivalents, and marketable securities totaled $486.3 million as of June 30, 2025, expected to fund operations into 2027.
• The company secured a collaboration and licensing agreement with Kaken for Envudeucitinib in dermatology in Japan, including $40 million in upfront and near-term payments and approximately $140 million in additional milestones and option fees, plus tiered royalties.

Sentiment

Score: 8

Explanation: The filing presents a highly positive outlook, emphasizing a robust late-stage pipeline with multiple near-term milestones, strong clinical data for its lead asset, a significant cash runway, and a strategic collaboration providing non-dilutive capital. The focus on validated targets and unmet needs in large markets further enhances the positive sentiment.

Positives

• Strong cash position of $486.3 million as of June 30, 2025, providing runway into 2027.
• De-risked portfolio with TYK2 inhibitors targeting genetically and clinically validated pathways across multiple diseases.
• Envudeucitinib Phase 2 STRIDE trial in Psoriasis met primary and secondary endpoints with high statistical significance at Week 12 (PASI 75: p < 0.001).
• Envudeucitinib demonstrated a well-tolerated safety profile with no major safety signals identified up to two years of active therapy in Psoriasis.
• Envudeucitinib's PASI 75 OLE response rates approach market-leading injectables, indicating potential for best-in-class oral therapy.
• A-005, a first-in-class CNS-penetrant TYK2 inhibitor, demonstrated full CNS penetration and maximal target inhibition in Phase 1, with significant preclinical efficacy in EAE models for MS.
• Lonigutamab offers a potentially differentiated anti-IGF-1R therapy for Thyroid Eye Disease with a unique mechanism of action and subcutaneous auto-injector formulation.
• The Kaken collaboration provides $40 million in non-dilutive capital, extending the cash runway and validating Envudeucitinib's commercial potential in Japan.

Negatives

• The development program for Lonigutamab is currently undergoing evaluation, indicating potential uncertainty or strategic review for this asset.

Risks

• Adverse effects from economic, business, and/or competitive factors.
• Risks that anticipated benefits and synergies of the recent merger with ACELYRIN, Inc. may not be fully realized or may take longer than expected.
• Challenges inherent in developing, commercializing, manufacturing, launching, marketing, and selling potential existing and new product candidates.
• Uncertainties regarding the scope, progress, results, and costs of developing product candidates, including preclinical studies and clinical trials.
• Timing and costs involved in obtaining and maintaining regulatory approval for current or future product candidates.
• Market for, adoption, pricing, and reimbursement of product candidates, if approved, and their ability to compete with rapidly growing and evolving therapies.
• Uncertainties in contractual relationships, including collaborations, partnerships, licensing, or other arrangements, and the performance of third-party suppliers and manufacturers.
• Ability to establish and maintain intellectual property protection for products or avoid or defend claims of infringement.
• Potential delays in initiating, enrolling, or completing preclinical studies and clinical trials.

Future Outlook

Alumis expects Envudeucitinib Phase 3 top-line data for Psoriasis in early Q1 2026, followed by a potential NDA filing. Phase 2b top-line data for SLE is anticipated in Q3 2026. The company plans to initiate a Phase 2 study for A-005 in Multiple Sclerosis in 1H 2026 and expects Phase 1 data for its next program (undisclosed target) in 2026. The cash runway is projected to extend into 2027.

Management Comments

• No direct quotes from company management were provided in the filing.

Industry Context

The filing highlights Alumis's focus on precision immunology, particularly with TYK2 inhibitors, a class of drugs gaining significant attention for their potential in various autoimmune diseases. The emphasis on oral therapies addresses a significant unmet need and patient preference in large markets like Psoriasis, where over 75% of patients prefer oral treatment over biologics. The development of a CNS-penetrant TYK2 inhibitor (A-005) positions Alumis uniquely in neuroinflammatory and neurodegenerative diseases like MS. The anti-IGF-1R therapy (Lonigutamab) for Thyroid Eye Disease aims to offer a safer alternative to existing treatments, addressing a key patient concern (e.g., hearing loss).

Comparison to Industry Standards

• Envudeucitinib's Phase 2 clinical response rates (PASI 75) in Psoriasis approach those of market-leading injectables such as Skyrizi (IL-23), Cosentyx (IL-17), and Stelara (IL-12/23), positioning it as a potential best-in-disease oral therapy.
• Envudeucitinib's complete inhibition of TYK2 is hypothesized to deliver better clinical results compared to other TYK2 inhibitors like Deucravacitinib and TAK-279, based on in vitro and Phase 1/2 biomarker data.
• A-005 is presented as a first-in-class brain-penetrant TYK2 inhibitor, addressing a gap in MS therapies that currently do not simultaneously target microglia and inflammation directly in the brain.
• Lonigutamab's unique non-competitive mechanism of action for anti-IGF-1R therapy is designed to potentially offer an improved safety profile, particularly regarding hearing loss, compared to existing IGF-1R therapies like Teprotumumab/Veligrotug, which are associated with elevated IGF-1 levels.

Stakeholder Impact

• Shareholders: Potential for significant value creation through successful clinical development and commercialization of late-stage assets, extended cash runway, and strategic partnerships.
• Patients: Development of potentially best-in-class oral therapies for Psoriasis, SLE, MS, and a safer anti-IGF-1R therapy for TED addresses significant unmet medical needs.
• Investment Professionals/Analysts: Provides updated data and timelines for key pipeline assets, aiding in valuation and investment decisions.
• Regulatory Authorities: Progress in clinical trials and potential NDA filings indicate future engagement for market approval.

Next Steps

• Early Q1 2026: Envudeucitinib Psoriasis Phase 3 top-line data for 16 and 24 week endpoints.
• 1H 2026: Initiate Phase 2 in Multiple Sclerosis for A-005.
• 3Q 2026: Envudeucitinib SLE Phase 2b top-line data.
• 2H 2026: Phase 1 clinical data for the next program (undisclosed target).
• Continue evaluation of the Lonigutamab development program.
• Potential NDA filing for Envudeucitinib in Psoriasis following Phase 3 data.

Key Dates

Keywords

Alumis, TYK2 inhibitor, Envudeucitinib, A-005, Lonigutamab, Psoriasis, Systemic Lupus Erythematosus, Multiple Sclerosis, Thyroid Eye Disease, Immunology, Clinical Trials, Biotechnology, Pharmaceuticals, Drug Development, SEC Filing